Helena Canhão, Augusto Faustino, João Eurico Fonseca ... 2012.pdf · João Eurico Fonseca...
59
Helena Canhão, Augusto Faustino, João Eurico Fonseca Comissão Coordenadora Reuma.pt SPR XVI CPR, Vilamoura 5 Maio 2012 www.reuma.pt [email protected]
Transcript of Helena Canhão, Augusto Faustino, João Eurico Fonseca ... 2012.pdf · João Eurico Fonseca...
Helena Canhatildeo Augusto Faustino
Joatildeo Eurico Fonseca
Comissatildeo Coordenadora Reumapt
SPR
XVI CPR Vilamoura 5 Maio 2012
wwwreumapt Reumaptspreumatologiapt
PRESENTATION OUTLINE
Brief history and aims overtime
Reumapt overview
What is new in the web version
How to apply
What have we learned from Reumapt
Ongoing research projects
Collaborations
Next steps and future directions
Brief history and Aims overtime
2006-2008 Set up a national register to follow up distinct cohorts of rheumatic patients treated with synthetic andor biological therapies Use validated instruments to assess outcomes accepted by all rheumatologists Structured collection of data Screens were like electronic medical records linked to a SQL server database
2008-2010 Increase the number of participating centers Improve quality of data Consolidate funding
2010-2012 Achieve 2000 RA patients Develop a web version Submit first scientific papers
Rheumatoid Arthritis
DMARD Bio
2285 891
Rheumatoid Arthritis
Ankylosing Spondylitis
DMARD Bio DMARD Bio
2285 891 327 402
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
PRESENTATION OUTLINE
Brief history and aims overtime
Reumapt overview
What is new in the web version
How to apply
What have we learned from Reumapt
Ongoing research projects
Collaborations
Next steps and future directions
Brief history and Aims overtime
2006-2008 Set up a national register to follow up distinct cohorts of rheumatic patients treated with synthetic andor biological therapies Use validated instruments to assess outcomes accepted by all rheumatologists Structured collection of data Screens were like electronic medical records linked to a SQL server database
2008-2010 Increase the number of participating centers Improve quality of data Consolidate funding
2010-2012 Achieve 2000 RA patients Develop a web version Submit first scientific papers
Rheumatoid Arthritis
DMARD Bio
2285 891
Rheumatoid Arthritis
Ankylosing Spondylitis
DMARD Bio DMARD Bio
2285 891 327 402
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Brief history and Aims overtime
2006-2008 Set up a national register to follow up distinct cohorts of rheumatic patients treated with synthetic andor biological therapies Use validated instruments to assess outcomes accepted by all rheumatologists Structured collection of data Screens were like electronic medical records linked to a SQL server database
2008-2010 Increase the number of participating centers Improve quality of data Consolidate funding
2010-2012 Achieve 2000 RA patients Develop a web version Submit first scientific papers
Rheumatoid Arthritis
DMARD Bio
2285 891
Rheumatoid Arthritis
Ankylosing Spondylitis
DMARD Bio DMARD Bio
2285 891 327 402
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Rheumatoid Arthritis
DMARD Bio
2285 891
Rheumatoid Arthritis
Ankylosing Spondylitis
DMARD Bio DMARD Bio
2285 891 327 402
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Rheumatoid Arthritis
Ankylosing Spondylitis
DMARD Bio DMARD Bio
2285 891 327 402
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
DMARD Bio DMARD Bio DMARD Bio DMARD Bio
2285 891 327 402 219 230 423 122
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
2285 891 327 402 219 230 423 122 249 40
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
0
1000
2000
3000
4000
5000
6000
200
8-0
6
200
8-0
7
200
8-0
8
200
8-0
9
200
8-1
0
200
8-1
1
200
8-1
2
200
9-0
1
200
9-0
2
200
9-0
3
200
9-0
4
200
9-0
5
200
9-0
6
200
9-0
7
200
9-0
8
200
9-0
9
200
9-1
0
200
9-1
1
200
9-1
2
2010
-01
2010
-02
2010
-03
2010
-04
2010
-05
2010
-06
2010
-07
2010
-08
2010
-09
2010
-10
2010
-11
2010
-12
2011
-01
2011
-02
2011
-03
2011
-04
2011
-05
2011
-06
2011
-07
2011
-08
2011
-09
2011
-10
2011
-11
2011
-12
2012
-01
2012
-02
2012
-03
Number of patients
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Total number of visits ndash 32092
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic arthritis
Juvenile arthritis
Mixed
DMARD Bio DMARD Bio DMARD Bio DMARD Bio No bio Bio
8178 11043 803 5148 529 2072 2309 1300 456 254
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
0
5000
10000
15000
20000
25000
30000
35000
Number of visits
Reg AR
Bio AR
Reg EA
Bio EA
Reg AP
Bio AP
Reg AIJ
Bio AIJ
Reg Ger
Bio Ger
Total
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Reumapt overview
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
What is new in the web version
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
34
Continua hellip
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
35
Continua hellip
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
36
Continua hellip
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
38
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
39
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
41
Continua hellip
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
42
Detalhes hellip
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
44
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
45
Detalhes hellip
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
46
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
47
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
How to apply
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Reumapt is accessed online from any computer
wwwreumapt
Login with username and password Centers already using desktop version Contact between local and SPR informatics staff Migrate data Discontinue desktop version First Reumapt users Fill in the application form available at wwwreumapt and send it to Reumaptspreumatologiapt
How to apply
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
What have we learned from Reumapt
BioRePortAP an electronic clinical record coupled with a
database an example of its use in a single centre Aims Evaluate the efficacy and safety of the treatment of PsA patients with anti-TNF in the Rheumatology Dept of Hospital de Santa Maria using the BioRePortAP Conclusions The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs
Raquel Campanilho-Marques et al Acta Reumatol Port 2010 35 176-83
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Reumapt - the rheumatic diseases Portuguese register
Aims Describe the structure of Reumapt and the population registered since June 2008 Conclusions Registers are crucial to ensure correct clinical use adequate assessment of post-marketing biological therapies efficacy and safety thus contributing for a better cost-benefit ratio Reumapt is a powerful and accurate tool to answer to these unmet needs It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve rheumatic patients care
Helena Canhatildeo et al Acta Reumatol Port 20113645-56
What have we learned from Reumapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive
Aims To investigate the switches performed in patients with rheumatoid arthritis under biological therapy and specifically comparing the switches from earlier days with more recent switches Conclusions Switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy A trend towards a better and more targeted control of the disease could be discussed in light of our results Although switches were more frequently performed in more recent years in older patients and with a shorter duration of biological therapy there is still room for improvement when aiming at remission for example by applying a tighter therapy strategy like the treat to target model
Sofia Ramiro et al Acta Reumatol Port 2011 36 234-42
What have we learned from Reumapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Similar effectiveness over one year between anti-TNF drugs first user patients with rheumatoid arthritis
Higher level education predicts better response
Smoking concomitant corticotherapy ACPA and higher disease activity assessed by physician at baseline predict worse response
Canhatildeo H Rheumatology (submitted)
What have we learned from Reumapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
What have we learned from Reumapt
TRAF1C5 locus is associated with response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis
Canhao H et al Arthritis Research Therapy (submitted)
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Ongoing research projects
Predictors of treatment response in patients with ankylosing spondylitis Biologic drug efficacy and treatment discontinuation in rheumatoid arthritis patients treated with biological therapies Understanding physicians decision to switch or keeping treatment regimen - is it dependent on patients outcome measures To boost and improve quality of reumapt data Clinical serological and genetic predictors of evolution outcome and response to treatment in Portuguese patients with Juvenile Idiopathic Arthritis Genetic predictors of severity in patients with RA
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Collaborations
IMM Biobank
METEOR
Sociedade Portuguesa de Pediatria
Cererra
EpiReumaPt CoReumapt
Direcccedilatildeo Geral de Sauacutede
Sociedades Portuguesas de Dermatologia Gastroenterologia
Medicina Interna
Centro de Imunodeficiecircncias Primaacuterias CHLN IMM
RELESER
Pharmaceutical companies (IIS)
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Next steps and future directions
2012-2014
Implement Reumapt web-based version always looking for the best quality of data Cover ~100 of rheumatology centers Research papers published in high impact journals Close established relationships and collaborations set-up new ones
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
Obrigada
Todos os Reumatologistas e
Centros Publicos e Privados de Reumatologia que inserem dados
Fernando Martins ndash informatico da SPR
Patrocinadores para projectos especiacuteficos MSD Pfizer Abbott
wwwreumapt Reumaptspreumatologiapt
